← FDA Drug Approvals (Drugs@FDA)
NINTEDANIB
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: GLENMARK PHARMS LTD · Approved 2026-03-26
Drug application
- FDA Application #
ANDA212555- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- NINTEDANIB
- Generic name
- Nintedanib Esylate
- Active ingredients
- NINTEDANIB ESYLATE
- Dosage form
- CAPSULE
- Route
- ORAL
- Marketing status
- None (Tentative Approval)
- Sponsor
- GLENMARK PHARMS LTD
- First approval
- 2026-03-26
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown